Business Description
Nkarta Inc
NAICS : 541714
SIC : 2834
ISIN : US65487U1088
Share Class Description:
NKTX: Ordinary SharesTotal Employee Number:
108Description
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.07 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.26 | |||||
Debt-to-EBITDA | -0.7 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 17 | |||||
3-Year EPS without NRI Growth Rate | 18.6 | |||||
3-Year FCF Growth Rate | 20.1 | |||||
3-Year Book Growth Rate | -16.7 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.08 | |||||
9-Day RSI | 52.35 | |||||
14-Day RSI | 51.26 | |||||
3-1 Month Momentum % | 43.38 | |||||
6-1 Month Momentum % | 69.73 | |||||
12-1 Month Momentum % | 83.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 12.96 | |||||
Quick Ratio | 12.96 | |||||
Cash Ratio | 12.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.3 | |||||
Shareholder Yield % | 2.89 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -29.87 | |||||
ROA % | -23.54 | |||||
ROIC % | -72.18 | |||||
3-Year ROIIC % | -26.54 | |||||
ROC (Joel Greenblatt) % | -112.92 | |||||
ROCE % | -28.71 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.8 | |||||
Price-to-Tangible-Book | 0.8 | |||||
EV-to-EBIT | -0.64 | |||||
EV-to-Forward-EBIT | -0.38 | |||||
EV-to-EBITDA | -0.7 | |||||
EV-to-FCF | -0.85 | |||||
| Price-to-Net-Current-Asset-Value | 1.53 | |||||
| Price-to-Net-Cash | 1.59 | |||||
Earnings Yield (Greenblatt) % | -156.25 | |||||
FCF Yield % | -38.37 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NKTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nkarta Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.34 | ||
| Beta | 2.2693 | ||
| 3-Year Sharpe Ratio | 0.3 | ||
| 3-Year Sortino Ratio | 0.65 | ||
| Volatility % | 61.29 | ||
| 14-Day RSI | 51.26 | ||
| 14-Day ATR ($) | 0.219069 | ||
| 20-Day SMA ($) | 2.732 | ||
| 12-1 Month Momentum % | 83.63 | ||
| 52-Week Range ($) | 1.68 - 3.65 | ||
| Shares Outstanding (Mil) | 71.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nkarta Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nkarta Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 131 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 41 days | ||
| H.C. Wainwright 4th Annual Cell Therapy Virtual Conference | 2026-06-30 14:00 | 2.85 (+0.71%) | ||
| General meeting for 2026 | 2026-06-10 13:00 | 2.45 (+1.24%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 3.18 (-0.62%) | ||
| 25th Annual Needham Virtual Healthcare Conference. | 2026-04-15 11:45 | 2.29 (-0.43%) | ||
| Annual report for 2025 | 2026-03-25 | 2.05 (-5.96%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-25 | 2.05 (-5.96%) | ||
| Leerink Global Healthcare Conference | 2026-03-10 10:40 | 2.58 (+6.17%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 09:10 | 2.70 (+4.25%) |
Show
Entries
Nkarta Inc Frequently Asked Questions
What is Nkarta Inc(NKTX)'s stock price today?
The current price of NKTX is $3.22. The 52 week high of NKTX is $3.65 and 52 week low is $1.68.
When is next earnings date of Nkarta Inc(NKTX)?
The next earnings date of Nkarta Inc(NKTX) is 2026-08-12 Est..
Does Nkarta Inc(NKTX) pay dividends? If so, how much?
Nkarta Inc(NKTX) does not pay dividend.
Guru Commentaries on NAS:NKTX
No articles.
Press Release
Articles on Nkarta Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers